Litigation Details for CyDex Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

CyDex Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Docket		Date Filed	2017-12-20
Court	District Court, D. Delaware	Date Terminated	2019-11-06
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICALS USA, INC.
Patents	8,410,077; 9,200,088; 9,493,582
Attorneys	Karen Elizabeth Keller
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for CyDex Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2017-12-20	1		and lawfully issued United States Patent No. 8,410,077 (“the ’077 patent”), entitled “Sulfoalkyl Ether …such patents to this lawsuit. COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 8,410,077 …“Notification of Certification for U.S. Patent Nos. 8,410,077; 9,200,088; and 9,493,582 Pursuant to §…interest in the ’077 patent, the ’088 patent, and the ’582 patent (collectively, “the patents-in-suit”). … 1. This is an action for patent infringement under the patent laws of the United States arising	External link to document
2019-11-06	116	SO ORDERED	quot;) for infringement of United States Patent Nos. 8,410,077, 9,200,088, and 9,493 ,582 (…JUDGMENT AND DISMISSAL ORDER This action for patent infringement (the "Litigation") has been… (collectively, the "CyDex Patents"). CyDex' s commencement of the Litigation… § 355U)(2)(A)(vii)(IV) directed to the CyDex Patents and seeking approval to market a generic melphalan…injection prior to the expiration of the CyDex Patents. CyDex and Teva have agreed to enter into	External link to document
2017-12-20	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,410,077 B2; 9,200,088 B2; 9,493,582…2017 6 November 2019 1:17-cv-01832 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document